WuXi AppTec and WuXi Biologics Weigh Asset Sales in US and Europe Over Biosecure Act Concerns
Reports emerged last week in the Financial Times suggesting that WuXi AppTec (HKG: 2359) and...
HKG: 2269
WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million
HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi XDC Accelerates Bioconjugate Drug Development with 67.6% YOY Revenue Increase in H1 2024
HONG KONG—WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi...
WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors
WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China,...
WuXi AppTec and WuXi Bio Shares Rally as US Biosecure Act Excluded from Defense Bill
Shares of Chinese Contract Development and Manufacturing Organizations (CDMOs) WuXi AppTec (SHA: 603259) and WuXi...
WuXi Biologics Expands Manufacturing Capacity with New Bioreactors at Hangzhou Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
Landmark Biosecure Act Passes US House Committee with 40-1 Vote, Eyes 2024 Enactment
The US House Committee on Oversight and Accountability has completed the markup process for amendments...
WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions
WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...
US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns
US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...
WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi Biologics Launches WuXiaADCC PLUS Platform for Non-Fucosylated Antibody Development
WuXi Biologics (HKG: 2269), a Contract Research, Development, and Manufacturing Organization (CRDMO) based in China,...
WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent
WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...
WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...